Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Neoplasms, Germ Cell and Embryonal 1Medulloblastoma 1Hepatoblastoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Cyclophosphamide 4Etoposide 3pembrolizumab 2fludarabine 2etoposide phosphate 2Sirolimus 2Paclitaxel 2Mesna 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Cisplatin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2tremelimumab 1ripretinib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1guadecitabine 1fosaprepitant 1fludarabine phosphate 1durvalumab 1bintrafusp alfa protein, human 1avelumab 1Vorinostat 1Ursodeoxycholic Acid 1Topotecan 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × Ursodeoxycholic Acid × Genitourinary × Clear all
NCT01505569 2024-02-26

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Masonic Cancer Center, University of Minnesota

Phase NA Completed
44 enrolled
CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Brain Neoplasms, Carcinoma, Renal Cell, Medulloblastoma, Neoplasms, Germ Cell and Embryonal, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡